Cannabinoid and Spilanthol Fixed-Dose Combination for Inflammatory Disorders
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current medical treatments for conditions such as inflammatory bowel disease, non-alcoholic steatohepatitis, and other inflammatory and autoimmune disorders often have limited efficacy and may involve significant side effects, with a need for more effective and synergistic therapeutic approaches.
Innovation Solution
The development of fixed-dose combination compositions comprising therapeutically effective amounts of cannabinoids, such as CBD, and spilanthol, either as isolates or components of plant extracts or essential oils, which are administered together to achieve synergistic, additive, or potentiating therapeutic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If single-agent therapies are used, then treatment simplicity is maintained, but therapeutic efficacy is limited
Solution Approach 1:
The patent combines multiple active ingredients (cannabinoids and spilanthol) into a single fixed-dose combination composition, merging their therapeutic effects to achieve enhanced efficacy while maintaining simple administration as a single dosage form
Solution Approach 2:
The invention creates a composite therapeutic composition containing both cannabinoids and spilanthol in specific ratios, leveraging the synergistic properties of different chemical compounds to produce a therapeutic effect greater than individual components alone
2Reliability
If combination therapies are used, then therapeutic efficacy is enhanced, but treatment complexity increases
Solution Approach 1:
The patent merges multiple medications into one fixed-dose combination product, allowing patients to administer a single dosage form that contains both cannabinoids and spilanthol in predetermined ratios, thereby simplifying the administration process while maintaining enhanced therapeutic efficacy
3Object-affected harmful factors
If conventional treatments are used, then treatment protocol simplicity is maintained, but side effects are significant
Solution Approach 1:
The invention formulates a composite composition containing cannabinoids and spilanthol in specific ratios that leverage the beneficial properties of each component while minimizing their respective side effects, creating a safer therapeutic profile
Solution Approach 2:
The patent optimizes the dosage ratios of cannabinoids to spilanthol in the fixed-dose combination, adjusting the concentration parameters to achieve maximum therapeutic effect with minimum side effects
Data Source
AI summary
Provided herein are fixed-dose combination (FDC) compositions comprising therapeutically effective amounts of at least one cannabinoid and spilanthol whether as essentially pure isolates or synthetics or as components of essential oils or plant extracts or combinations thereof. The compositions are formulated as pharmaceutical compositions, nutraceuticals, cosmeceuticals, nutricosmetics, cosmetics, or food products. The pharmaceutical compositions are useful for the treatment of a gastro-enteric disease selected from the group consisting of irritable bowel disease, Crohn's disease, colitis, irritable bowel syndrome, and acute and chronic pancreatitis or of sepsis. Other pharmaceutical uses are as anti-allergic, anti-inflammatory, immunomodulator, antioxidant, anti-microbial, antibacterial, antifungal, antiviral, antinociceptive, analgesic, anesthetic, anti-cancer, apoptosis inducing, antiscorbutic, antipyretic, anti-malarial, addiction mitigatory, anxiolytic, anti-depressant, diuretic, anti-diarrheal, vasodilator or aphrodisiac agents. The pharmaceutical compositions of this invention exhibit a synergistic effect.